Skip to main content

Naftidrofuryl









Naftidrofuryl


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search
















































































Naftidrofuryl
Naftidrofuryl.svg
Clinical data
Trade names Praxilene

AHFS/Drugs.com
 International Drug Names
Routes of
administration		 Oral
ATC code

  • C04AX21 (WHO)
Legal status
Legal status


  • UK: POM (Prescription only)



Pharmacokinetic data
Metabolism Hepatic
Elimination half-life
 1 - 3.5 hours
Identifiers
CAS Number

  • 31329-57-4 ☑Y

PubChem CID
  • 4417
ChemSpider

  • 4264 ☑Y
UNII
  • 42H8PQ0NMJ
ChEMBL
  • ChEMBL1620794
ECHA InfoCard
100.045.960 Edit this at Wikidata
Chemical and physical data
Formula
C24H33NO3
Molar mass 383.524 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
  (verify)

Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized).[1][2][3] Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.


Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.


Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[4]


Naftidrofuryl may be effective for relieving the pain of muscle cramps.[5]



Adverse Effects[edit]


Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.[6]



See also[edit]



  • Ketanserin

  • Sarpogrelate



References[edit]





  1. ^ Peter Lanzer; Eric J. Topol (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN 978-94-011-4439-1.


  3. ^ Aly, Saida Abdel Regal; Hossain, Murad; Bhuiyan, Mohiuddin Ahmed; Nakamura, Takashi; Nagatomo, Takafumi (2009). "Assessment of Binding Affinity to 5-Hydroxytryptamine 2A (5-HT2A) Receptor and Inverse Agonist Activity of Naftidrofuryl: Comparison With Those of Sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–450. doi:10.1254/jphs.09124FP. ISSN 1347-8613.


  4. ^ "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". www.der-arzneimittelbrief.de.


  5. ^ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.


  6. ^ Brayfield, A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.















Retrieved from "https://en.wikipedia.org/w/index.php?title=Naftidrofuryl&oldid=873603967"





Navigation menu


























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.776","walltime":"0.930","ppvisitednodes":{"value":4824,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":304101,"limit":2097152},"templateargumentsize":{"value":4070,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":17510,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 636.208 1 -total"," 63.70% 405.279 1 Template:Drugbox"," 46.60% 296.477 1 Template:Infobox"," 22.48% 143.043 1 Template:Reflist"," 20.37% 129.620 18 Template:Navbox"," 12.66% 80.541 16 Template:Unbulleted_list"," 12.07% 76.821 2 Template:Cite_book"," 9.06% 57.650 1 Template:Serotonergics"," 6.17% 39.270 1 Template:Infobox_drug/chemical_formula"," 5.50% 35.000 2 Template:Cite_journal"]},"scribunto":{"limitreport-timeusage":{"value":"0.255","limit":"10.000"},"limitreport-memusage":{"value":4680889,"limit":52428800}},"cachereport":{"origin":"mw1224","timestamp":"20181213234418","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Naftidrofuryl","url":"https://en.wikipedia.org/wiki/Naftidrofuryl","sameAs":"http://www.wikidata.org/entity/Q425867","mainEntity":"http://www.wikidata.org/entity/Q425867","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2006-08-06T07:34:15Z","dateModified":"2018-12-13T23:44:26Z","image":"https://upload.wikimedia.org/wikipedia/commons/c/c5/Naftidrofuryl.svg","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":117,"wgHostname":"mw1274"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校
Read more

13 indicted, 8 arrested in Calif. drug cartel investigation

Image
Fox News U.S. World Opinion Politics Entertainment Business Lifestyle TV Radio More Expand / Collapse search Login Watch TV ☰ Hot Topics U.S. Crime Military Education Terror Immigration Economy Personal Freedoms World U.N. Conflicts Terrorism Disasters Global Economy Environment Religion Scandals Opinion Politics Executive Senate House Judiciary Foreign policy Polls Elections Entertainment Celebrity News Movies TV News Music News Style News Entertainment Video Business Markets Politics Technology Features Business Leaders Lifestyle Food + Drink Cars + Trucks Travel + Outdoors House + Home Fitness + Well-being Style + Beauty Family Science Archaeology Air & Space Planet Earth Wild Nature Natural Science Dinosaurs Tech Security Innovation Drones Computers Video Games Military Tech Health Healthy Living Medical Research Mental Health Cancer Heart Health Children'
Read more